Non-survivor patients with malignant middle cerebral artery infarction showed persistently high serum malondialdehyde levels.
Ischemic stroke
Malondialdehyde
Mortality
Patients
Prognosis
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
17 Oct 2019
17 Oct 2019
Historique:
received:
01
08
2019
accepted:
27
09
2019
entrez:
19
10
2019
pubmed:
19
10
2019
medline:
7
1
2020
Statut:
epublish
Résumé
Previously there have been found higher circulating malondialdehyde levels during the first week of ischemic stroke in patients with worst neurological functional outcome, and at moment of ischemic stroke in non-survivor patients. Thus, the aim of our study was to determine the potential role of serum malondialdehyde levels during the first week of a severe cerebral infarction to mortality prediction. This study was observational, prospective, and multicenter. We included patients with a severe malignant middle cerebral artery infarction (MMCAI) defined as patients with computed tomography showing acute infarction in more than of 50% of the territory and Glasgow Coma Scale (GCS) lower than 9. We determined serum concentrations of malondialdehyde on days 1, 4 and 8 of MMCAI. Serum malondialdehyde concentrations at days 1 (p < 0.001), 4 (p < 0.001), and 8 (p = 0.001) of MMCAI in non-survivor patients (n = 34) were higher than in survivor patients (n = 34). ROC curve analyses showed that serum malondialdehyde concentrations at days 1, 4, and 8 of MMCAI had an AUC (95% CI) to predict 30-day mortality of 0.77 (0.65-0.86; p < 0.001), 0.82 (0.69-0.91; p < 0.001) and 0.84 (0.70-0.93; p < 0.001) respectively. The new findings of our study were that serum malondialdehyde levels during the first week of MMCAI could be used as biomarkers to mortality prediction.
Identifiants
pubmed: 31623565
doi: 10.1186/s12883-019-1479-z
pii: 10.1186/s12883-019-1479-z
pmc: PMC6798363
doi:
Substances chimiques
Biomarkers
0
Malondialdehyde
4Y8F71G49Q
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
238Subventions
Organisme : Fundación DISA a la Investigación Médica 2017 (Santa Cruz de Tenerife. Spain).
ID : OA18/011
Références
Methods Enzymol. 1990;186:421-31
pubmed: 2233309
Angiology. 2014 Sep;65(8):667-76
pubmed: 24132856
Clin Sci (Lond). 2004 Nov;107(5):477-84
pubmed: 15279619
Lancet. 1974 Jul 13;2(7872):81-4
pubmed: 4136544
Free Radic Res. 2002 Mar;36(3):265-8
pubmed: 12071344
Biomed Res Int. 2014;2014:256879
pubmed: 24895559
Atherosclerosis. 2015 Jul;241(1):192-8
pubmed: 26016451
Clin Chem. 2006 Apr;52(4):601-23
pubmed: 16484333
J Clin Neurosci. 2007 Nov;14(11):1062-6
pubmed: 17884504
Crit Care Med. 1985 Oct;13(10):818-29
pubmed: 3928249
J Pineal Res. 2014 Aug;57(1):110-9
pubmed: 24867613
Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(12 Pt 2):36-42
pubmed: 22792747
J Matern Fetal Neonatal Med. 2012 Apr;25 Suppl 1:119-24
pubmed: 22348528
PLoS One. 2015 May 01;10(5):e0125893
pubmed: 25933254
Neurochem Int. 2013 Apr;62(5):712-8
pubmed: 23201332
Folia Neuropathol. 2012;50(3):219-30
pubmed: 23023336
CNS Neurol Disord Drug Targets. 2013 Aug;12(5):698-714
pubmed: 23469845
J Exp Biol. 2004 Aug;207(Pt 18):3221-31
pubmed: 15299043
Eur J Clin Nutr. 2005 Dec;59(12):1367-73
pubmed: 16091766
J Pineal Res. 2000 Nov;29(4):217-27
pubmed: 11068944
Stroke. 2007 May;38(5):1655-711
pubmed: 17431204
JPEN J Parenter Enteral Nutr. 2006 Mar-Apr;30(2):108-14
pubmed: 16517955
Anal Biochem. 1992 May 1;202(2):249-55
pubmed: 1519749
J Pineal Res. 2011 Apr;50(3):292-303
pubmed: 21210839
Life Sci. 2014 Apr 1;100(2):97-109
pubmed: 24530291